Combination of CD 160 and CD 200 as a useful tool for differential diagnosis between chronic lymphocytic leukemia and other mature B‐cell neoplasms

• Published in: International journal of laboratory hematology Vol. 37; no. 4; pp. 486 - 494
• Main Authors: Lesesve, J.‐F., Tardy, S., Frotscher, B., Latger‐Cannard, V., Feugier, P., De Carvalho Bittencourt, M.
• Format: Journal Article
• Language: English
• Published: 01-08-2015
• ISSN: 1751-5521; 1751-553X
• DOI: 10.1111/ijlh.12315

Summary
Introduction
Chronic lymphocytic leukemia is usually diagnosed through the characteristic morphology/immunophenotype of the lymphocytes, but some
CLL
cases remain atypical resulting in diagnostic uncertainty.
Methods
Using flow cytometry analysis, we investigated the expression of
CD
s160/200 on B cells from 124 patients (82
CLL
, 42 other B‐cell neoplasms) and nine controls.
CD
s160/200 measurements were determined as a ratio of the mean fluorescence intensities of leukemic cells/controls and were considered positive when the ratios were ≥2 and 20, respectively.
Results
Sixty and 83%
CLL
expressed
CD
s160/200 as compared to 5% and 10% of other B‐cell neoplasms, respectively. None of the controls showed
CD
s160/200 expressions. Combination of both markers was observed in 55% of
CLL
but only in 2% of other B‐cell neoplasms, and absence of both markers occurred in 12% of
CLL
but in 86% of other B‐cell neoplasms.
Conclusion
CD
s160/200 were associated with markers of the gold standard ‘Matutes score’ and could be useful markers to differentiate atypical
CLL
from other B‐cell neoplasms in the absence of available biopsies or cytogenetics and molecular studies.